Vertex Pharma Says Kalydeco Showed Lung Function Improvement, Improvements Durable Up to 96 Weeks

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) announced today new data from a long-term follow-up study that showed that the improvements in lung function (forced expiratory volume in one second, FEV[1]), respiratory symptoms and weight gain among people who were treated with KALYDECO™ (ivacaftor)for 48 weeks in one of two pivotal studies (STRIVE or ENVISION) were durable for up to 96 total weeks of treatment

(c) 2013 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.